Details of the Drug

General Information of Drug (ID: DMS4BLQ)

Drug Name

Aminolevulinic acid hci

Synonyms

Aminolevulinic acid; 5-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid; 106-60-5; 5-Aminolevulinate; delta-aminolevulinic acid; Pentanoic acid, 5-amino-4-oxo-; Aladerm; 5-Amino-4-oxovaleric acid; Kerastick; Ameluz; Aminolevulinate; 5-ALA; delta-ALA; 5-Amino-4-oxopentanoate; 5-amino-levulinate; 5-amino-levulinic acid; 5-amino-4-oxo-pentanoic acid; CCRIS 8958; UNII-88755TAZ87; EINECS 203-414-1; Levulinic acid, 5-amino-; CHEMBL601; 4-oxo-5-amino-pentanoic acid; CHEBI:17549; ZGXJTSGNIOSYLO-UHFFFAOYSA-N; 88755TAZ87; Levulan (TN)

Indication

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[1]
Actinic keratosis	EK90.0	Approved	[2]
Astrocytoma	2A00.0Y	Approved	[3]
Glioblastoma	2A00	Approved	[4]
Malignant glioma	2A00.0	Approved	[5]
Oral mucosa leukoplakia	N.A.	Approved	[6]
Adult glioblastoma	N.A.	Investigative	[7]
Cervical Intraepithelial neoplasia	2E66.1	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Affected Organisms

Humans and other mammals

ATC Code

L01XD04: Aminolevulinic acid hci

L01XD: Sensitizers used in photodynamic/radiation therapy

L01X: OTHER ANTINEOPLASTIC AGENTS

L01: ANTINEOPLASTIC AGENTS

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

131.13

Logarithm of the Partition Coefficient (xlogp)

-3.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Bioavailability: The bioavailability of drug is 50-60% []
Clearance: The drug present in the plasma can be removed from the body at the rate of 1.88 mL/min/kg [9]
Half-life: The concentration or amount of drug in body reduced by one-half in 0.70 +/-0.18 hours [9]
Metabolism: The drug is metabolized via skin []
Unbound Fraction: The unbound fraction of drug in plasma is 0.88% [9]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.12 L/kg [9]

Chemical Identifiers

Formula: C5H9NO3
IUPAC Name: 5-amino-4-oxopentanoic acid
Canonical SMILES: C(CC(=O)O)C(=O)CN
InChI: InChI=1S/C5H9NO3/c6-3-4(7)1-2-5(8)9/h1-3,6H2,(H,8,9)
InChIKey: ZGXJTSGNIOSYLO-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 137
ChEBI ID: CHEBI:17549
CAS Number: 106-60-5
UNII: 88755TAZ87
DrugBank ID: DB00855
TTD ID: D0Y7ZD
VARIDT ID: DR00057
INTEDE ID: DR0088

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Delta-aminolevulinic acid dehydratase (ALAD)	TTJHKYD	HEM2_HUMAN	Inhibitor	[10]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Peptide transporter 2 (SLC15A2)	DT8QKNP	S15A2_HUMAN	Substrate	[11]
Proton-coupled amino acid transporter 1 (SLC36A1)	DT48WEM	S36A1_HUMAN	Substrate	[12]
Peptide transporter 1 (SLC15A1)	DT9G7XN	S15A1_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Porphobilinogen synthase (ALAD)_{Main DME}	DETBNY4	HEM2_HUMAN	Substrate	[14]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[15]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[15]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[16]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Gene/Protein Processing	[17]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Gene/Protein Processing	[18]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Gene/Protein Processing	[19]
FAS-associated death domain protein (FADD)	OTV7GFHH	FADD_HUMAN	Post-Translational Modifications	[17]
Interstitial collagenase (MMP1)	OTI4I2V1	MMP1_HUMAN	Gene/Protein Processing	[20]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Protein Interaction/Cellular Processes	[17]
Stromelysin-1 (MMP3)	OTGBI74Z	MMP3_HUMAN	Gene/Protein Processing	[20]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4784).
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Physical approaches to treat glioblastoma. Curr Opin Oncol. 2020 Nov;32(6):640-649.
4	Comparison of commercial 5-aminolevulinic acid (Gliolan?) and the pharmacy-compounded solution fluorescence in glioblastoma. Acta Neurochir (Wien). 2019 Aug;161(8):1733-1741.
5	Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006 May;7(5):392-401.
6	Vascular alterations after photodynamic therapy mediated by 5-aminolevulinic acid in oral leukoplakia. Lasers Med Sci. 2017 Feb;32(2):379-387.
7	5-Aminolevulinic acid-guided resection improves the overall survival of patients with glioblastoma-a comparative cohort study of 343 patients. Neurooncol Adv. 2021 Mar 26;3(1):vdab047.
8	Photodetection and Safety of 5-Aminolevulinic Acid-Induced Porphyrin in Patients With Cervical Intraepithelial Neoplasia. Lasers Surg Med. 2021 Jul;53(5):654-663.
9	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10	Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9.
11	PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes. Brain Res. 2006 Nov 29;1122(1):18-23.
12	Delta-aminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1). Br J Pharmacol. 2010 Mar;159(6):1339-53.
13	Transport of the photodynamic therapy agent 5-aminolevulinic acid by distinct H+-coupled nutrient carriers coexpressed in the small intestine. J Pharmacol Exp Ther. 2010 Jan;332(1):220-8.
14	Modifying effects of delta-Aminolevulinate dehydratase polymorphism on blood lead levels and ALAD activity. Toxicol Lett. 2018 Oct 1;295:351-356.
15	Effect and mechanism of 5-aminolevulinic acid-mediated photodynamic therapy in esophageal cancer. Lasers Med Sci. 2011 Jan;26(1):69-78. doi: 10.1007/s10103-010-0810-0. Epub 2010 Jul 30.
16	Photodynamic therapy with 5-aminolevulinic acid induces apoptosis and caspase activation in malignant T cells. J Cutan Med Surg. 2001 Jan-Feb;5(1):8-13. doi: 10.1177/120347540100500103.
17	5-aminolevulinic acid induce apoptosis via NF-B/JNK pathway in human oral cancer Ca9-22 cells. J Oral Pathol Med. 2011 Jul;40(6):483-9. doi: 10.1111/j.1600-0714.2010.00973.x. Epub 2010 Dec 8.
18	Massive apoptotic cell death of human glioma cells via a mitochondrial pathway following 5-aminolevulinic acid-mediated photodynamic therapy. J Neurooncol. 2007 Jul;83(3):223-31. doi: 10.1007/s11060-006-9325-8. Epub 2007 Jan 24.
19	Study of the efficacy and mechanism of ALA-mediated photodynamic therapy on human hepatocellular carcinoma cell. Liver Int. 2007 Mar;27(2):201-8. doi: 10.1111/j.1478-3231.2006.01412.x.
20	Influence of 5-aminolevulinic acid and red light on collagen metabolism of human dermal fibroblasts. J Invest Dermatol. 2003 Feb;120(2):325-31. doi: 10.1046/j.1523-1747.2003.12037.x.